CRA provided expert reports and trial testimony in a breach of contract litigation involving the development of a novel botanical drug on behalf of the defendant. The plaintiff licensor alleged that the licensee had failed to appropriately develop the product pursuant to its contractual obligations. CRA assessed the licensee’s commercial launch plan and its investments in the development process with respect to the licensee’s “commercially reasonable efforts” obligations and the potential market for the novel product.
2023 International Arbitration review: Updates and trends
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...